Imo-8400    (DrugBank: -)

1 disease
IDDisease name (Link within this page)Number of trials
50Dermatomyositis4

50. Dermatomyositis    [ 157 clinical trials,   207 drugs,   (DrugBank: 76 drugs),   47 drug target genes,   142 drug target pathways]
Searched query = "Dermatomyositis", "Polymyositis"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
4 / 157 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2015-003277-15-SE
(EUCTR)
12/04/201722/06/2016A Phase 2 Study of IMO-8400 in Patients with DermatomyositisA Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial of IMO-8400 in Patients with Dermatomyositis Dermatomyositis
MedDRA version: 19.1;Level: PT;Classification code 10012503;Term: Dermatomyositis;System Organ Class: 10040785 - Skin and subcutaneous tissue disorders;Therapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17]
Product Name: IMO-8400
Product Code: IMO-8400
INN or Proposed INN: IMO-8400
Product Name: IMO-8400
Product Code: IMO-8400
INN or Proposed INN: IMO-8400
Idera Pharmaceuticals, Inc.NULLNot RecruitingFemale: yes
Male: yes
36Phase 2United States;Hungary;Czech Republic;United Kingdom;Sweden
2EUCTR2015-003277-15-GB
(EUCTR)
02/09/201631/12/2015A Phase 2 Study of IMO-8400 in Patients with DermatomyositisA Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial of IMO-8400 in Patients with Dermatomyositis Dermatomyositis
MedDRA version: 19.1;Level: PT;Classification code 10012503;Term: Dermatomyositis;System Organ Class: 10040785 - Skin and subcutaneous tissue disorders ;Therapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17]
Idera Pharmaceuticals, Inc.NULLNot Recruiting Female: yes
Male: yes
36Phase 2United States;Hungary;Czech Republic;United Kingdom;Sweden
3EUCTR2015-003277-15-HU
(EUCTR)
12/08/201620/06/2016A Phase 2 Study of IMO-8400 in Patients with DermatomyositisA Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial of IMO-8400 in Patients with Dermatomyositis Dermatomyositis
MedDRA version: 19.0;Level: PT;Classification code 10012503;Term: Dermatomyositis;System Organ Class: 10040785 - Skin and subcutaneous tissue disorders;Therapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17]
Product Name: IMO-8400
Product Code: IMO-8400
INN or Proposed INN: IMO-8400
Idera Pharmaceuticals, Inc.NULLNot RecruitingFemale: yes
Male: yes
36Phase 2United States;Czech Republic;Hungary;United Kingdom;Sweden
4NCT02612857
(ClinicalTrials.gov)
November 201518/11/2015Trial of IMO-8400 in Adult Patients With DermatomyositisA Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial of IMO-8400 in Patients With DermatomyositisDermatomyositisDrug: IMO-8400 Dose Group 1;Drug: IMO-8400 Dose Group 2;Drug: PlaceboIdera Pharmaceuticals, Inc.NULLCompleted18 Years75 YearsAll30Phase 2United States;Hungary;United Kingdom